Paper71446
Prostaglandins and breast cancer.
Bennett A and 5 others. Lancet, 1977. Cited by 278 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Prostaglandins and breast cancer. Papers, record 71446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/71446
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Neoplasms | Major topic |
| Breast Neoplasms | Major topic |
| Neoplasm Invasiveness | Major topic |
| Prostaglandins E | Major topic |
| Prostaglandins F | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aspirin | |
| Female | |
| Humans | |
| In Vitro Techniques | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasms | |
| Prostaglandin Antagonists |
Source PubMed
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 278 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34,203,324 | Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects. | Molecules | 2021 | https://conductscience.org/library/papers/34203324 | PubMed |
| 32,545,461 | Low-Dose Aspirin Use Significantly Improves the Survival of Late-stage NPC: A Propensity Score-Matched Cohort Study in Taiwan. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32545461 | PubMed |
| 30,999,962 | Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. | Breast Cancer Res | 2019 | https://conductscience.org/library/papers/30999962 | PubMed |
| 28,597,105 | Role of Aspirin in Breast Cancer Survival. | Curr Oncol Rep | 2017 | https://conductscience.org/library/papers/28597105 | PubMed |
| 28,271,910 | Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. | Expert Opin Investig Drugs | 2017 | https://conductscience.org/library/papers/28271910 | PubMed |
| 28,160,159 | Aspirin use is associated with lower mammographic density in a large screening cohort. | Breast Cancer Res Treat | 2017 | https://conductscience.org/library/papers/28160159 | PubMed |
| 24,816,739 | COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients. | Med Oncol | 2014 | https://conductscience.org/library/papers/24816739 | PubMed |
| 24,789,723 | Cyclooxygenase-2 polymorphisms and breast cancer associated risk in Pakistani patients. | Pathol Oncol Res | 2015 | https://conductscience.org/library/papers/24789723 | PubMed |
| 23,607,319 | The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. | Thyroid | 2013 | https://conductscience.org/library/papers/23607319 | PubMed |
| 23,576,215 | Nutrient intake and nutrient patterns and risk of lung cancer among heavy smokers: results from the COSMOS screening study with annual low-dose CT. | Eur J Epidemiol | 2013 | https://conductscience.org/library/papers/23576215 | PubMed |
| 23,566,419 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. | Breast Cancer Res | 2013 | https://conductscience.org/library/papers/23566419 | PubMed |
| 22,002,714 | Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. | Cancer Metastasis Rev | 2011 | https://conductscience.org/library/papers/22002714 | PubMed |
| 20,396,544 | Clinical value of cyclooxygenase-2 expression in human breast carcinoma. | Cancer Res Treat | 2004 | https://conductscience.org/library/papers/20396544 | PubMed |
| 20,159,825 | Aspirin intake and survival after breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20159825 | PubMed |
| 18,792,778 | Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. | Breast Cancer Res Treat | 2009 | https://conductscience.org/library/papers/18792778 | PubMed |
| 16,497,869 | Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. | J Clin Pathol | 2006 | https://conductscience.org/library/papers/16497869 | PubMed |
| 15,123,779 | Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. | J Leukoc Biol | 2004 | https://conductscience.org/library/papers/15123779 | PubMed |
| 14,587,862 | COX-2 inhibitors for the prevention of breast cancer. | J Mammary Gland Biol Neoplasia | 2003 | https://conductscience.org/library/papers/14587862 | PubMed |
| 14,586,398 | Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. | Oncogene | 2003 | https://conductscience.org/library/papers/14586398 | PubMed |
| 12,884,024 | Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. | J Cancer Res Clin Oncol | 2003 | https://conductscience.org/library/papers/12884024 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/71446
GET https://conductscience.org/api/papers/v1/71446/cited_by?page=2